AT12800U1 - Pharmazeutisches Präparat zur Verwendung bei der oralen Kontrazeption von Frauen mit Laktoseintoleranz - Google Patents

Pharmazeutisches Präparat zur Verwendung bei der oralen Kontrazeption von Frauen mit Laktoseintoleranz Download PDF

Info

Publication number: AT12800U1
Authority: AT; Austria
Prior art keywords: cma; pharmaceutical preparation; preparation according; lactose; avicel
Prior art date: 2007-11-05

Application number

ATGM371/2010U

Other languages

German (de)

English (en)

Original Assignee

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-05

Filing date

2007-11-05

Publication date

2012-11-15

2007-11-05 Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag

2007-11-05 Priority to ATGM371/2010U priority Critical patent/AT12800U1/de

2012-11-15 Publication of AT12800U1 publication Critical patent/AT12800U1/de

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 20
201000010538 Lactose Intolerance Diseases 0.000 title abstract description 17
239000000203 mixture Substances 0.000 claims abstract description 12
229920002678 cellulose Polymers 0.000 claims abstract description 11
239000011230 binding agent Substances 0.000 claims abstract description 10
239000000583 progesterone congener Substances 0.000 claims abstract description 10
239000001913 cellulose Substances 0.000 claims abstract description 9
229940011871 estrogen Drugs 0.000 claims abstract description 9
239000000262 estrogen Substances 0.000 claims abstract description 9
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 23
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 20
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 20
229960002568 ethinylestradiol Drugs 0.000 claims description 20
239000008101 lactose Substances 0.000 claims description 20
229960003309 dienogest Drugs 0.000 claims description 12
AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims description 12
235000010980 cellulose Nutrition 0.000 claims description 10
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
239000008108 microcrystalline cellulose Substances 0.000 claims description 8
229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 7
QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 claims description 7
229960001616 chlormadinone acetate Drugs 0.000 claims description 7
229960005309 estradiol Drugs 0.000 claims description 6
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 5
238000009826 distribution Methods 0.000 claims description 5
229930182833 estradiol Natural products 0.000 claims description 5
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
229960004400 levonorgestrel Drugs 0.000 claims description 5
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
229920003084 Avicel® PH-102 Polymers 0.000 claims description 3
239000005913 Maltodextrin Substances 0.000 claims description 3
239000000945 filler Substances 0.000 claims description 3
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
229940035034 maltodextrin Drugs 0.000 claims description 3
108010010803 Gelatin Proteins 0.000 claims description 2
229920002774 Maltodextrin Polymers 0.000 claims description 2
229920002472 Starch Polymers 0.000 claims description 2
229920000159 gelatin Polymers 0.000 claims description 2
239000008273 gelatin Substances 0.000 claims description 2
235000019322 gelatine Nutrition 0.000 claims description 2
235000011852 gelatine desserts Nutrition 0.000 claims description 2
239000008107 starch Substances 0.000 claims description 2
235000019698 starch Nutrition 0.000 claims description 2
239000000902 placebo Substances 0.000 claims 6
229940068196 placebo Drugs 0.000 claims 6
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
102000013265 Syntaxin 1 Human genes 0.000 claims 1
108010090618 Syntaxin 1 Proteins 0.000 claims 1
WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 abstract description 3
238000011321 prophylaxis Methods 0.000 abstract description 3
230000007774 longterm Effects 0.000 abstract 1
239000004480 active ingredient Substances 0.000 description 15
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
238000009472 formulation Methods 0.000 description 7
229940127234 oral contraceptive Drugs 0.000 description 6
239000003539 oral contraceptive agent Substances 0.000 description 6
239000008187 granular material Substances 0.000 description 5
102100026189 Beta-galactosidase Human genes 0.000 description 4
108010059881 Lactase Proteins 0.000 description 4
108010005774 beta-Galactosidase Proteins 0.000 description 4
238000005469 granulation Methods 0.000 description 4
230000003179 granulation Effects 0.000 description 4
229940116108 lactase Drugs 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
206010000060 Abdominal distension Diseases 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
208000024330 bloating Diseases 0.000 description 3
235000013339 cereals Nutrition 0.000 description 3
229960001681 croscarmellose sodium Drugs 0.000 description 3
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
238000000034 method Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000000470 constituent Substances 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
239000012738 dissolution medium Substances 0.000 description 2
238000007922 dissolution test Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
229940071676 hydroxypropylcellulose Drugs 0.000 description 2
229960003943 hypromellose Drugs 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
229960001652 norethindrone acetate Drugs 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000009827 uniform distribution Methods 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
235000015173 baked goods and baking mixes Nutrition 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
235000008429 bread Nutrition 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
235000019219 chocolate Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
235000020247 cow milk Nutrition 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
229940079919 digestives enzyme preparation Drugs 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
229960004766 estradiol valerate Drugs 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
235000020190 lactose-free milk Nutrition 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
235000013580 sausages Nutrition 0.000 description 1
238000005204 segregation Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
238000012819 small-bowel biopsy Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Reproductive Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

ATGM371/2010U 2007-11-05 2007-11-05 Pharmazeutisches Präparat zur Verwendung bei der oralen Kontrazeption von Frauen mit Laktoseintoleranz AT12800U1 (de)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
ATGM371/2010U AT12800U1 (de)	2007-11-05	2007-11-05	Pharmazeutisches Präparat zur Verwendung bei der oralen Kontrazeption von Frauen mit Laktoseintoleranz

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07021465A EP2055306A1 (de)	2007-11-05	2007-11-05	Verwendung eines Gestagens in Kombination mit einem Estrogen und einem oder mehreren pharmazeutisch annehmbaren hilfsstoffen/Trägern zur laktosefreien oralen Kontrazeption
ATGM371/2010U AT12800U1 (de)	2007-11-05	2007-11-05	Pharmazeutisches Präparat zur Verwendung bei der oralen Kontrazeption von Frauen mit Laktoseintoleranz

Publications (1)

Publication Number	Publication Date
AT12800U1 true AT12800U1 (de)	2012-11-15

Family

ID=39016019

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ATGM371/2010U AT12800U1 (de)	2007-11-05	2007-11-05	Pharmazeutisches Präparat zur Verwendung bei der oralen Kontrazeption von Frauen mit Laktoseintoleranz

Country Status (30)

Country	Link
EP (3)	EP2055306A1 (pt)
JP (1)	JP2011502136A (pt)
KR (1)	KR20100103794A (pt)
CN (1)	CN101848716B (pt)
AR (1)	AR069195A1 (pt)
AT (1)	AT12800U1 (pt)
AU (1)	AU2008324549A1 (pt)
BR (1)	BRPI0819189A2 (pt)
CA (1)	CA2704523A1 (pt)
CO (1)	CO6270329A2 (pt)
CR (1)	CR11413A (pt)
DE (1)	DE202007019049U1 (pt)
DK (1)	DK2217243T3 (pt)
DO (1)	DOP2010000130A (pt)
EA (1)	EA201000749A1 (pt)
EC (1)	ECSP10010152A (pt)
ES (1)	ES2511841T3 (pt)
HR (1)	HRP20140962T1 (pt)
IL (1)	IL205349A0 (pt)
MX (1)	MX2010004975A (pt)
NZ (1)	NZ585065A (pt)
PA (1)	PA8803001A1 (pt)
PE (1)	PE20091020A1 (pt)
PL (1)	PL2217243T3 (pt)
PT (1)	PT2217243E (pt)
SG (1)	SG188118A1 (pt)
TW (1)	TW200936142A (pt)
UY (1)	UY31454A1 (pt)
WO (1)	WO2009059690A1 (pt)
ZA (1)	ZA201004024B (pt)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0368373A1 (en) *	1988-10-13	1990-05-16	Akzo Nobel N.V.	Multi-phase contraceptive preparation
EP0514967A1 (en) *	1991-05-16	1992-11-25	Sterling Winthrop Inc.	Low solubility drug-coated bead compositions
WO1995005807A1 (en) *	1993-08-20	1995-03-02	Novo Nordisk A/S	A novel pharmaceutical for oral administration comprising progesterone and a polyethylene glycol together with an excipient
JPH1171268A (ja) *	1997-08-28	1999-03-16	Kayaku:Kk	性ホルモン含有錠剤
EP0911029A2 (en) *	1997-06-23	1999-04-28	Medical College Of Hampton Roads	Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
WO2003041720A1 (fr) *	2001-11-13	2003-05-22	Besins International Belgique	Composition pharmaceutique a base de progesterone micronisee, son procede de preparation et ses utilisations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2260673A1 (en)	1999-02-04	2000-08-04	Natrel Inc.	A process for making a lactose-free milk without negatively affecting the organoleptic properties thereof; and milk so processed
DE10043846A1 (de) *	2000-09-04	2002-04-04	Jenapharm Gmbh	17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
PL1670440T3 (pl)	2003-09-29	2014-11-28	Novo Nordisk Healthcare Ag	Preparaty HRT
WO2005030176A1 (en)	2003-09-29	2005-04-07	Novo Nordisk Femcare Ag	Improved stability of progestogen formulations
CN1672685A (zh) *	2004-03-26	2005-09-28	董可娟	一种新的避孕药物
DE102004019406A1 (de) *	2004-04-19	2005-11-03	Schering Ag	17α-Fluorsteroide
DE102004026670A1 (de) *	2004-05-28	2005-12-15	Grünenthal GmbH	Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de) *	2004-05-28	2005-12-15	Grünenthal GmbH	Darreichungsform zur hormonalen Kontrazeption
EP1690543A1 (de) *	2005-02-15	2006-08-16	Schering AG	Pharmazeutisches Präparat zur Kontrazeption
EP1774970A1 (de) *	2005-10-13	2007-04-18	Bayer Schering Pharma AG	Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest

2007
- 2007-11-05 EP EP07021465A patent/EP2055306A1/de not_active Withdrawn
- 2007-11-05 AT ATGM371/2010U patent/AT12800U1/de not_active IP Right Cessation
- 2007-11-05 DE DE202007019049U patent/DE202007019049U1/de not_active Expired - Lifetime
2008
- 2008-10-22 WO PCT/EP2008/008900 patent/WO2009059690A1/de not_active Ceased
- 2008-10-22 KR KR1020107012376A patent/KR20100103794A/ko not_active Ceased
- 2008-10-22 BR BRPI0819189-1A patent/BRPI0819189A2/pt not_active IP Right Cessation
- 2008-10-22 MX MX2010004975A patent/MX2010004975A/es not_active Application Discontinuation
- 2008-10-22 ES ES08847408.5T patent/ES2511841T3/es active Active
- 2008-10-22 DK DK08847408.5T patent/DK2217243T3/da active
- 2008-10-22 PL PL08847408T patent/PL2217243T3/pl unknown
- 2008-10-22 JP JP2010531446A patent/JP2011502136A/ja not_active Ceased
- 2008-10-22 EP EP08847408.5A patent/EP2217243B1/de active Active
- 2008-10-22 PT PT88474085T patent/PT2217243E/pt unknown
- 2008-10-22 EP EP14164080.5A patent/EP2774614A1/de not_active Withdrawn
- 2008-10-22 HR HRP20140962AT patent/HRP20140962T1/hr unknown
- 2008-10-22 AU AU2008324549A patent/AU2008324549A1/en not_active Abandoned
- 2008-10-22 SG SG2013008883A patent/SG188118A1/en unknown
- 2008-10-22 CN CN2008801148441A patent/CN101848716B/zh not_active Expired - Fee Related
- 2008-10-22 NZ NZ585065A patent/NZ585065A/en not_active IP Right Cessation
- 2008-10-22 EA EA201000749A patent/EA201000749A1/ru unknown
- 2008-10-22 CA CA2704523A patent/CA2704523A1/en not_active Abandoned
- 2008-11-04 PE PE2008001887A patent/PE20091020A1/es not_active Application Discontinuation
- 2008-11-04 UY UY31454A patent/UY31454A1/es unknown
- 2008-11-05 AR ARP080104837A patent/AR069195A1/es unknown
- 2008-11-05 TW TW097142714A patent/TW200936142A/zh unknown
- 2008-11-06 PA PA20088803001A patent/PA8803001A1/es unknown
2010
- 2010-04-26 IL IL205349A patent/IL205349A0/en unknown
- 2010-05-05 CR CR11413A patent/CR11413A/es not_active Application Discontinuation
- 2010-05-05 DO DO2010000130A patent/DOP2010000130A/es unknown
- 2010-05-05 EC EC2010010152A patent/ECSP10010152A/es unknown
- 2010-05-05 CO CO10053517A patent/CO6270329A2/es not_active Application Discontinuation
- 2010-06-04 ZA ZA2010/04024A patent/ZA201004024B/en unknown

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0368373A1 (en) *	1988-10-13	1990-05-16	Akzo Nobel N.V.	Multi-phase contraceptive preparation
EP0514967A1 (en) *	1991-05-16	1992-11-25	Sterling Winthrop Inc.	Low solubility drug-coated bead compositions
WO1995005807A1 (en) *	1993-08-20	1995-03-02	Novo Nordisk A/S	A novel pharmaceutical for oral administration comprising progesterone and a polyethylene glycol together with an excipient
EP0911029A2 (en) *	1997-06-23	1999-04-28	Medical College Of Hampton Roads	Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
JPH1171268A (ja) *	1997-08-28	1999-03-16	Kayaku:Kk	性ホルモン含有錠剤
WO2003041720A1 (fr) *	2001-11-13	2003-05-22	Besins International Belgique	Composition pharmaceutique a base de progesterone micronisee, son procede de preparation et ses utilisations

Also Published As

Publication number	Publication date
HK1145289A1 (en)	2011-04-15
ES2511841T3 (es)	2014-10-23
EP2217243A1 (de)	2010-08-18
AR069195A1 (es)	2010-01-06
WO2009059690A1 (de)	2009-05-14
NZ585065A (en)	2012-06-29
CN101848716B (zh)	2012-11-28
DK2217243T3 (da)	2014-10-20
DOP2010000130A (es)	2010-07-31
PT2217243E (pt)	2014-09-24
UY31454A1 (es)	2009-05-29
EA201000749A1 (ru)	2010-12-30
DE202007019049U8 (de)	2010-09-30
PL2217243T3 (pl)	2014-12-31
CR11413A (es)	2010-06-17
TW200936142A (en)	2009-09-01
EP2055306A1 (de)	2009-05-06
DE202007019049U1 (de)	2010-05-12
PA8803001A1 (es)	2009-06-23
KR20100103794A (ko)	2010-09-28
PE20091020A1 (es)	2009-08-15
CO6270329A2 (es)	2011-04-20
IL205349A0 (en)	2010-12-30
EP2774614A1 (de)	2014-09-10
MX2010004975A (es)	2010-05-24
EP2217243B1 (de)	2014-08-06
CN101848716A (zh)	2010-09-29
AU2008324549A1 (en)	2009-05-14
ZA201004024B (en)	2012-11-28
SG188118A1 (en)	2013-03-28
JP2011502136A (ja)	2011-01-20
ECSP10010152A (es)	2010-06-29
CA2704523A1 (en)	2009-05-14
BRPI0819189A2 (pt)	2015-05-26
HRP20140962T1 (hr)	2014-12-05

Legal Events

Date

Code

Title

Description

2013-10-15

PC

Change of the owner

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

Effective date: 20130910

2016-07-15

MM01

Lapse because of not paying annual fees

Effective date: 20151130

Publication	Publication Date	Title
DE69621588T2 (de)	2003-01-30	Kontrollierte Freisetzung von Steroiden aus Zuckerüberzügen
EP2131847B1 (de)	2010-12-29	Arzneimittel umfassend wenigstens ein gestagen
DE69710756T2 (de)	2002-10-24	Orale zeitversetzt schnell freisetzende formulierung sowie verfahren zu deren herstellung
DE69930157T2 (de)	2006-08-31	Triphasisches, orales kontrazeptivum
EP2124972B1 (de)	2012-06-13	Verwendung einer zusammensetzung aus mineralstoffen und gegebenenfalls acetogenen und/oder butyrogenen bakterien zur vermeidung oder reduzierung von gasbildung im dickdarm eines säugetiers und dadurch bedingter abdominaler beschwerden
DE69604600T2 (de)	2000-02-24	Neue Zuckerbeschichtungszusammensetzung zum Auftragen auf komprimierte Wirkstofftabletten
DE60203929T2 (de)	2006-01-19	Behandlungsverfahren und pharmazeutische zusammensetzung zur notfall-empfängnisverhütung
US20080038350A1 (en)	2008-02-14	Low-dosage peroral medication for contraception containing crystalline dienogest and ethinyl estradiol
DE2542158A1 (de)	1976-04-01	Pharmazeutisches mittel fuer die verabreichung in der mundhoehle und verfahren zu seiner herstellung
DE69430580T2 (de)	2002-08-29	Arzneimittel in nahrungsmittelform
DE19834931A1 (de)	2000-02-24	Verwendung von biogenen Estrogenen zur Hormonsubstitutionstherapie
US20090117184A1 (en)	2009-05-07	Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception
EP2217243B1 (de)	2014-08-06	Gestagen in kombination mit einem estrogen und einem oder mehreren pharmazeutisch annehmbaren hilfsstoffen/ trägern zur laktosefreien oralen kontrazeption
EP1848406B1 (de)	2008-05-14	Feste perorale arzneiform zur kontrazeption, die dienogest und ethinylestradiol enthält
EP1690529A1 (de)	2006-08-16	Feste perorale Arzneiform zur Kontrazeption, die Dienogest und Ethinylestradiol enthält
WO2008017331A2 (de)	2008-02-14	Perorale arzneiform mit dienogest und ethinylestradiol zur kontrazeption
EP3090638A1 (de)	2016-11-09	Nahrungsergänzung zur behandlung von vitamin-d3-mangelerscheinungen
EP4724046A1 (de)	2026-04-15	Verwendung kohlenhydrathaltiger zusammensetzungen in tablettenform zur behandlung von hypoglykämiezuständen
EP2020235A1 (de)	2009-02-04	einphasisches pharmazeutisches kombinationspräparat (dienogest und ethinylestradiol) zur oralen therapie der regulierung des blutdruckes
DE202022104209U1 (de)	2022-09-26	Moderne Wirkstoffformulierung für die Krebstherapie
WO2009015766A1 (de)	2009-02-05	Einphasisches pharmazeutisches kombinationspräparat (dienogest und ethinylestradiol) zur oralen therapie der regulierung des blutdruckes
HK1145289B (en)	2013-11-01	Use of a gestagen in combination with an estrogen and one or more pharmaceutically tolerable excipients/carriers for lactose-free oral contraceptive
EP2209475A2 (de)	2010-07-28	Verfahren zur herstellung eines einphasischen pharmazeutischen präparates zur begrenzung/minderung des risikos einer tiefen-venen-thrombose in einheit mit einer oralen kontrazeption
DE202010010589U1 (de)	2010-10-14	Estrogenfreie Formulierung zur oralen Kontrazeption, bevorzugt verwendbar für Frauen mit bewusster/unbewusster Laktoseintoleranz oder mit bewusster laktosefreier Kontrazeption